Skip to main content

Table 1 Unweighted patient demographic and baseline clinical characteristics a

From: Fractures in women treated with raloxifene or alendronate: a retrospective database analysis

  1-Year 3-Year 5-Year 6-Year 7-Year 8-Year
  RLX ALN RLX ALN RLX ALN RLX ALN RLX ALN RLX ALN
Number of Patients 23,243 72,055 9,758 24,221 3,141 6,652 1,246 2,465 650 1,053 217 331
  63.0 64.9 63.3 65.2 63.0 65.3 62.9 64.7 62.3 64.3 60.7 63.2
Age (Mean, SD) (9.5) (10.7)* (9.1) (10.3)* (8.8) (10.0)* (9.0) (9.8)* (8.8) (9.6)* (7.6) (9.0)*
Insurance Plan Typesb   *   *   *   *     
Comprehensive 43.0% 41.6% 50.0% 49.8% 55.8% 54.3% 55.9% 50.6% 60.9% 65.9% 54.4% 61.9%
Preferred provider organization 35.4% 33.9% 31.7% 29.6% 25.9% 23.8% 21.7% 19.1% 19.2% 14.5% 20.3% 11.8%
Point-of-service plan with capitation 6.1% 4.9% 7.4% 7.5% 11.3% 14.5% 17.9% 26.3% 16.3% 17.0% 23.5% 24.2%
Point-of-service plan 8.7% 6.9% 7.7% 5.7% 5.7% 4.3% 4.2% 3.8% 3.2% 2.5% 1.4% 1.8%
Health maintenance organization 6.1% 11.7% 3.0% 7.0% 1.1% 2.9% 0.3% 0.2% 0.3% 0.1% 0.5% 0.3%
Other/Unknown 0.6% 0.9% 0.2% 0.3% 0.1% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Medicare Eligibility 38.1% 46.0%* 41.4% 49.3%* 41.8% 52.1%* 42.1% 50.8%* 39.4% 49.0%* 28.1% 40.8%†
Urban Residence 71.8% 80.5%* 69.0% 77.6%* 64.2% 71.6%* 54.3% 58.8%† 43.5% 37.4%† 28.6% 16.9%†
Charlson Comorbidity Index (Mean, SD) 0.46 (0.95) 0.54 (1.10)* 0.44(0.91) 0.48 (1.02)* 0.42 (0.87) 0.44 (0.97) 0.47 (0.92) 0.45 (0.98) 0.44 (0.87) 0.45 (0.99) 0.46 (0.87) 0.51 (1.32)
BMD Screening 44.4% 71.4%* 40.0% 69.9%* 33.4% 68.5%* 34.0% 70.3%* 31.1% 70.2%* 24.9% 65.0%*
Pre-period Fracture 3.9% 7.7%* 3.5% 6.8%* 2.8% 5.8%* 3.4% 6.2%* 2.9% 6.3%† 3.2% 5.7%
Confounding Conditions  
Hypertension 26.6% 25.2%* 27.4% 24.9%* 27.9% 24.6%* 28.4% 25.7% 28.0% 24.6% 29.0% 21.8%
Other Cardiovascular Disease 17.6% 20.0%* 17.3% 19.8%* 16.5% 19.6%* 15.5% 19.1%† 14.6% 19.6%† 13.4% 20.2%†
Metabolic Disorders 15.6% 14.9%† 15.1% 14.3% 15.0% 13.8% 13.6% 13.4% 14.2% 13.7% 17.1% 14.8%
Diabetes 9.2% 7.8%* 9.8% 7.0%* 8.9% 6.4%* 8.0% 6.1%† 8.3% 5.9% 8.8% 7.3%
Osteoporosis 9.4% 12.9%* 8.4% 13.2%* 7.6% 13.2%* 7.2% 13.8%* 7.8% 14.7%* 9.7% 16.3%†
Dyslipidemia 7.0% 6.2%* 6.9% 6.1%† 6.8% 5.7%† 6.4% 5.4% 7.1% 5.2% 8.3% 4.5%
Rheumatoid arthritis 1.7% 2.2%* 1.5% 2.2%* 1.1% 2.1%* 1.1% 2.4%† 1.2% 2.4% 1.4% 1.8%
Vasomotor symptoms 4.1% 3.5%* 4.3% 4.1% 4.1% 4.9% 3.8% 6.0%† 3.2% 7.3%* 1.4% 7.9%*
Ischemic heart disease 7.5% 7.5% 7.4% 7.6% 7.3% 7.6% 6.7% 7.2% 5.4% 6.6% 4.1% 6.9%
Breast cancer 4.8% 6.2%* 4.5% 5.8%* 5.0% 5.3% 5.9% 5.8% 5.4% 6.4% 5.5% 6.6%
Reflux 3.8% 2.7%* 3.7% 2.3%* 3.6% 2.5%† 3.6% 2.4%† 3.5% 2.1% 2.8% 2.1%
Gastritis 1.8% 1.4%* 1.5% 1.3% 1.4% 1.4% 0.9% 1.5% 1.1% 1.9% 0.5% 3.0%†
Gastric ulcer 0.4% 0.2%* 0.3% 0.2% 0.2% 0.2% 0.1% 0.1% 0.0% 0.2% 0.0% 0.3%
Peptic ulcer 0.1% 0.1%† 0.1% 0.1% 0.1% 0.1% 0.2% 0.1% 0.3% 0.2% 0.5% 0.0%
Confounding Medications  
Glucocorticoids 17.6% 19.1%* 16.4% 16.7% 16.0% 15.2% 15.0% 15.8% 13.1% 15.6% 12.0% 14.8%
Anticonvulsants 6.1% 6.6%† 5.3% 5.2% 4.4% 4.5% 4.1% 3.8% 4.0% 2.9% 3.2% 2.7%
Immunosuppressants 1.7% 3.1%* 1.4% 2.5%* 1.1% 2.3%* 0.7% 2.2%† 0.9% 2.7%† 0.9% 3.3%
Hormone Deprivation Therapy 2.2% 3.8%* 2.0% 3.5%* 2.4% 2.9% 2.8% 2.8% 2.5% 2.5% 2.8% 3.3%
Estrogen/Hormone Therapy 43.3% 29.7%* 50.3% 38.2%* 52.6% 45.5%* 38.0% 43.3%† 36.5% 42.4%† 36.4% 41.1%
Pre-period All-cause Healthcare Cost ($, Mean, SD) 6,954 (18,238) 7,544 (15,012)* 5,750 (12,698) 6,032 (12,196) 5,154 (9,073) 5,370 (11,866) 4,673 (7,807) 4,970 (9,188) 4,311 (6,449) 4,594 (6,652) 4,358 (7,198) 4,708 (6,952)
Pre-period Osteoporosis-related Healthcare Cost ($, Mean, SD) 268 (1,780) 484 (2,903)* 225 (1,394) 416 (2,738)* 226 (1,724) 337 (1,597)† 243 (2,626) 327 (1,581) 134 (573) 375 (2,121)† 173 (940) 319 (1,699)
Provider closest to Index Prescription  
Specialist 38.6% 37.5%† 38.9% 38.8% 39.4% 40.5% 43.1% 43.0% 39.8% 41.2% 38.7% 40.5%
Primary Care 17.0% 17.1% 15.9% 16.4% 15.7% 14.8% 14.2% 15.1% 14.2% 16.6% 13.4% 16.6%
Other/Unknown 44.4% 45.4%† 45.3% 44.8% 44.9% 44.8% 42.7% 42.0% 46.0% 42.2% 47.9% 42.9%
  1. *P<0.001; †P<0.05.
  2. aDue to limited space, not all covariates included in the IPTW and Multivariate models are presented in Table 1. Data can be provided upon request.
  3. bChi-Square test is used to test differences in insurance plan type between RLX and ALN cohort.
  4. ALN=alendronate; BMD=bone mineral density; RLX=raloxifene; SD=standard deviation.